A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice

AIDS Research and Human Retroviruses

Volumn 24, Issue 2, 2008, Pages 207-217

  Shephard, Enid ^a   Burgers, Wendy A ^a   Van Harmelen, Joanne H ^a   Monroe, James E ^b   Greenhalgh, Trish ^b   Williamson, Carolyn ^a   Williamson, Anna Lise ^a,c,d  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Therion Biologics Corporation   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR7; CYTOKINE; DNA VACCINE; GAG PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 120; INTERLEUKIN 7 RECEPTOR; MICROSOMAL AMINOPEPTIDASE; NEF PROTEIN; PADGEM PROTEIN; RNA DIRECTED DNA POLYMERASE; SAAVI DNA C VACCINE; SAAVI MVA C VACCINE; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; VIRUS GENE;

AIDS VACCINES; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GENOTYPE; GUINEA PIGS; HIV ANTIBODIES; HIV-1; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; RECOMBINANT FUSION PROTEINS; SPLEEN; T-LYMPHOCYTE SUBSETS; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, DNA; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 39549123797     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0206     Document Type: Article

References (60)

1. Duerr A, Wasserheit JN, and Corey L: HIV vaccines: New frontiers in vaccine development. Clin Infect Dis 2006;43:500-511.
2. Rosenberg ES, Billingsley JM, Caliendo AM, et al.: Vigorous HIV-1-specific CD4(+) T cell responses associated with control of viremia. Science 1997;278:1447-1450.
3. + T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002;3:1061-1068.
4. Harari A, Petitpierre S, Vallelian F, and Pantaleo G: Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: Changes after antiretroviral therapy. Blood 2004;103:966-972.
5. + T cells. Blood 2006;107:4781-4789.
6. + T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007;1:46-53.
7. Geldmacher C, Currier JR, Hermann E, et al.: CD8 T-cell recognition of multiple epitopes within specific Gag regions is associated with maintenance of a low steady-state viremia in human immunodeficiency virus type 1-seropositive patients. J Virol 2007;81:2440-2448.
8. + central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 2006;312:1530-1533.
9. Mattapallil JJ, Hill B, Douek DC, and Roederer M: Systemic vaccination prevents the total destruction of mucosal CD4 T cells during acute SIV challenge. J Med Primatol 2006;35:217-224.
10. + T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004;200:761-770.
11. Lanzavecchia A, Sallusto F: Dynamics of T lymphocyte responses: Intermediates, effectors, and memory cells. Science 2000;290:92-97.
12. Barouch DH and Letvin NL: HIV escape from cytotoxic T lymphocytes: A potential hurdle for vaccines? Lancet 2004;364:10-11.
13. Letvin NL: Progress toward an HIV vaccine. Annu Rev Med 2005;56:213-223.
14. Amara RR, Villinger F, Altman JD, et al.: Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001;292:69-74.
15. Shiver JW, Fu TM, Chen L, et al.: Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002;415:331-335.
16. Sadagopal S, Amara RR, Montefiori DC, et al.: Signature for long-term vaccine-mediated control of a simian and human immunodeficiency virus 89.6P challenge: Stable low-breadth and low-frequency T-cell response capable of co-producing gamma interferon and interleukin-2. J Virol 2005;79:3243-3253.
17. Santra S, Seaman MS, Xu L, et al.: Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol 2005;79:6516-6522.
18. Mattapallil JJ, Douek DC, Buckler-White, et al.: Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J Exp Med 2006;203:1533-1541.
19. Nkolola JP, Wee EG, Im EJ, et al.: Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa. Gene Ther 2004;11:1068-1080.
20. Smith JM, Amara RR, McClure HM, et al.: Multiprotein HIV type 1 clade B DNA/MVA vaccine: Construction, safety, and immunogenicity in macaques. AIDS Res Hum Retroviruses 2004;20:654-665.
21. Gomez CE, Najera JL, Jimenez EP, et al.: Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC coexpressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Vaccine 2007;25:2863-2885.
22. Gomez CE, Najera JL, Jimenez V, et al.: Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine 2007;25:1969-1992.
23. Kumar S, Aggarwal P, Vajpayee M, Pandey RM, and Seth P: Development of a candidate DNA/MVA HIV-1 subtype C vaccine for India. Vaccine 2006;24:2585-2593.
24. International AIDS Vaccine Initiative: Ongoing trials of preventative HIV vaccines. IAVI Report 2007. http://www.iavireport.org/specials/ OngoingTrialsofPreventiveHIVVaccines.asp.
25. Hanke T, McMichael AJ, and Dorrell L: Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J Gen Virol 2007;88:1-12.
26. Sandström E: Multigene, multiclade HIV-1 plasmid DNA prime and MVA boost is safe and highly immunogenic in healthy human volunteers. Oral presentation, AIDS Vaccine 2006 Conference. Amsterdam, The Netherlands, August 29 to September 1, 2006.
27. Ramanathan V, Kumar M, Mahalingam J, et al.: A phase I study to evaluate the safety and immunogenicity of a recombinant modified vaccinia Ankara virus (TBC-M4) multigenic HIV subtype C vaccine. Poster presentation, AIDS Vaccine 2007 Conference, Seattle, WA, August 20-23, 2007.
28. Hemelaar J, Gouws E, Ghys PD, and Osmanov S: Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006;20:W13-W23.
29. Burgers WA, van Harmelen JH, Shephard E, et al.: Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial. J Gen Virol 2006;87:399-410.
30. Mata M and Paterson Y: Th1 T cell responses to HIV-1 Gag protein delivered by a Listeria monocytogenes vaccine are similar to those induced by endogenous listerial antigens. J Immunol 1999;163:1449-1456.
31. Im EJ, Saubi N, Virgili G, et al.: Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding. J Virol 2007;81:9408-9418.
32. Casimiro DR, Tang AM, Perry HC, et al.: Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene. J Virol 2002;76:185-194.
33. Lian Y, Srivastava I, Gomez-Roman VR, et al.: Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain. J Virol 2005;79:13338-13349.
34. Unsoeld H and Pircher H: Complex memory T-cell phenotypes revealed by coexpression of CD62L and CCR7. J Virol 2005;79:4510-4513.
35. Jackson SS, Schmitz JE, Kuroda MJ, et al.: Evaluation of CD62L expression as a marker for vaccine-elicited memory cytotoxic T lymphocytes. Immunology 2005;116:443-453.
36. + T cell subsets identified by expression of IL-7 receptor alpha and CD62L. J Immunol 2005;175:4686-4696.
37. Li M, Gao F, Mascola JR, et al.: Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005;79:10108-10125.
38. Hel Z, Tsai WP, Tryniszewska E, et al.: Improved protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes. J Immunol 2006;176:85-96.
39. Bevan MJ: Helping the CD8(+) T-cell response. Nat Rev Immunol 2004;4:595-602.
40. Sun JC, Williams MA, and Bevan MJ: CD4(+) T cells are required for the maintenance, not programming, of memory CD8(+) T cells after acute infection. Nat Immunol 2004;5:927-933.
41. Matloubian M, Concepcion RJ, Ahmed R: CD4(+) T-cells are required to sustain CD8(+) cytotoxic T cell responses during chronic viral infection. J Virol 1994;68:8056-8063.
42. Pantaleo G and Koup RA: Correlates of immune protection in HIV-1 infection: What we know, what we don't know, what we should know. Nat Med 2004;10:806-810.
43. Seaman MS, Peyerl FW, Jackson SS, et al.: Subsets of memory cytotoxic T lymphocytes elicited by vaccination influence the efficiency of secondary expansion in vivo. J Virol 2004;78:206-215.
44. Bachmann MF, Wolint P, Schwarz K, and Oxenius A: Recall proliferation potential of memory CD8(+) T cells and antiviral protection. J Immunol 2005;175:4677-4685.
45. Hovav AI, Cayabyab MJ, Panas MW, et al.: Rapid memory CD8+ T lymphocyte induction through priming with recombinant Mycobacterium smegmatis. J Virol 2007;81:74-83.
46. Cayabyab MJ, Hovav AI, Hsu T, et al.: Generation of CD8+ T cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env. J Virol 2006;80:1654-1662.
47. Wherry EJ and Ahmed R: Memory CD8 T-cell differentiation during viral infection. J Virol 2004;78:5535-5545.
48. Huster KM, Koffler M, Stemberger C, et al.: Unidirectional development of CD8(+) central memory T cells into protective Listeria-specific effector memory T cells. Eur J Immunol 2006;36:1453-1464.
49. Bachmann MF, Beerli RR, Agnellini P, et al.: Long-lived memory CD8(+) T cells are programmed by prolonged antigen exposure and low levels of cellular activation. Eur J Immunol 2006;36:842-854.
50. Kaech SM and Ahmed R: Memory CD8(+) T cell differentiation: Initial antigen encounter triggers a developmental program in naive cells. Nat Immunol 2001;2:415-422.
51. van Stipdonk MJB, Lemmens EE, and Schoenberger SP: Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat Immunol 2001;2:423-429.
52. Kaech SM, Tan JT, Wherry EJ, et al.: Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 2003;4:1191-1198.
53. Ramirez JC, Finke D, Esteban M, Kraehenbuhl J, and Acha-Orbea H: Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration. Arch Virol 2003;148:827-839.
54. Hanke T, McMichael AJ, Dennis MJ, et al.: Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice. Vaccine 2005;23:1507-1514.
55. Montefiori DC, Morris L, Ferrari G, and Mascola JR: Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination. Current Opin HIV AIDS 2007;21:169-176.
56. Edwards TG, Wyss S, Reeves JD, et al.: Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein. J Virol 2002;76:2683-2691.
57. Holl V, Peressin M, Decoville T, et al.: Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol 2006;80:6177-6181.
58. Aasa-Chapman MMI, Holuigue S, Aubin K, et al.: Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type I infection. J Virol 2005;79:2823-2830.
59. Gomez-Roman VR, Patterson LJ, Venzon D, et al.: Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 2005;174:2185-2189.
60. Gomez-Roman VP, Florese RH, Peng B, et al.: An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains. J Acquir Immune Defic Syndr 2006;43:270-277.